RANBAXY RECEIVES FINAL APPROVAL TO MANUFACTURE AND MARKET RANTM-AMLODIPINE TABLETS IN CANADA

Jul 20, 2009

Toronto, Canada – July 20, 2009 Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval in Canada to manufacture and market RanTM-Amlodipine Tablets, 5 & 10 mg (Amlodipine Besylate Tablets) from Health Canada, Therapeutic Products Directorate (TPD). Total generic market size of Amlodipine Besylate Tablets in Canada is $456 million ($CAD) [IMS-CDH: May 2009]. RanTM-Amlodipine Tablets are indicated and employed as an antihypertensive-antianginal agent. “We look forward to marketing both strengths of RanTM-Amlodipine tablets at an affordable price that will be beneficial to both the Canadian healthcare system, and most importantly, to Canadian patients. It should be noted that we have developed this dosage through the scientific skills and talents within our parent company, Ranbaxy Laboratories Limited, Gurgaon, India and will manufacture product at Ohm Laboratories, our North American manufacturing facility located in New Brunswick, New Jersey. Product will be offered to all classes of trade soon. We expect to start to gain formulary inclusions within a matter of weeks,” said Paul Drake, President, RPCI. Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system. Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries. Ranbaxy is a subsidiary of Daiichi Sankyo Company, Ltd. CONTACTS: Charles M. Caprariello Vice President, Corporate Communications Ranbaxy Inc. (609) 720-5615 Paul Drake President Ranbaxy Pharmaceuticals Canada, Inc (905) 219-8820